R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models, patient engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. R1 RCM was founded on 2003 and is based in Chicago, Illinois.

NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NYSE:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM INVESTIGATION NEWS: BFA Law Announces an Investigation into R1 RCM Inc. (NYSE:RCM) and the $13.25 Per Share Offer; Shareholders are Notified to Contact the Firm

NEW YORK, July 06, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NASDAQ:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM SHAREHOLDER ALERT: BFA Law Announces an Investigation into R1 RCM Inc. (NASDAQ:RCM) and the $13.25 Per Share Offer; Shareholders are Notified to Contact the Firm

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NYSE:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM INQUIRY ALERT: BFA Law Announces an Investigation into R1 RCM Inc. (NYSE:RCM) and the $13.25 Per Share Offer; Shareholders are Urged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NYSE:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM INQUIRY NOTICE: BFA Law Announces an Investigation into R1 RCM Inc. (NYSE:RCM) and the $13.25 Per Share Offer; Shareholders are Encouraged to Inquire about Your Rights

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NYSE:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM INVESTIGATION ALERT: BFA Law Announces an Investigation into R1 RCM Inc. (NYSE:RCM) and the $13.25 Per Share Offer; Shareholders are Notified to Inquire about Your Rights

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating the R1 RCM Inc. (NASDAQ:RCM) acquisition by New Mountain Capital for $13.25 per share. If you invested in R1 RCM, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/r1-rcm-inc.

RCM INVESTIGATION NOTICE: BFA Law Announces an Investigation into R1 RCM Inc. (NASDAQ:RCM) and the $13.25 Per Share Offer; Shareholders are Urged to Inquire about Your Rights

MURRAY, Utah, May 24, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 10:30am ET.

R1 RCM to Present at the 2024 Jefferies Global Healthcare Conference

R1 RCM Inc. (NASDAQ:RCM ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Evan Smith - Senior Vice President, Investor Relations Lee Rivas - Chief Executive Officer Jennifer Williams - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Craig Hettenbach - Morgan Stanley Elizabeth Anderson - Evercore Jailendra Singh - Truist Securities Sean Dodge - RBC Capital Markets George Hill - Deutsche Bank Jack Wallace - Guggenheim Securities Michael Cherny - Leerink Partners Sarah James - Cantor Fitzgerald Daniel Grosslight - Citi Jeff Garro - Stephens Richard Close - Canaccord Genuity Allen Lutz - Bank of America Operator Thank you for standing by and welcome to the R1 RCM First Quarter 2024 Earnings Conference Call. [Operator Instructions] A reminder that this conference is also being recorded.

R1 RCM Inc. (RCM) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for R1 RCM INC (RCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, R1 RCM INC (RCM) Q1 Earnings: A Look at Key Metrics

MURRAY, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months ended March 31, 2024 and updated full year 2024 outlook.

R1 RCM Reports First Quarter 2024 Results

MURRAY, Utah, April 30, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 2024 Bank of America Securities Health Care Conference on Thursday, May 16, 2024, at 11:00am ET.

R1 RCM to Present at the 2024 Bank of America Securities Health Care Conference

MURRAY, Utah, April 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended March 31, 2024, before market open on Wednesday, May 8, 2024 and host a conference call at 8:00 a.m. ET to review the results.

R1 RCM to Release First Quarter 2024 Results on May 8, 2024

Report highlights R1's commitment to corporate responsibility and sustainability across the company's global footprint Report highlights R1's commitment to corporate responsibility and sustainability across the company's global footprint

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report

AMN Healthcare Services

Ready Capital Corp

AMN, RCM and RC have been added to the Zacks Rank #5 (Strong Sell) List on March 12, 2024.

New Strong Sell Stocks for March 12th

NEW YORK--(BUSINESS WIRE)---- $RCM #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of R1 RCM Inc. (“R1” or “the Company”) (NASDAQ: RCM). Investors who purchased R1 securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCM. Investigation Details: The investigation concerns whether RCM and its board violated the federal securities laws and/or breached their fid.

R1 RCM Inc. (RCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

R1 RCM Inc. (NASDAQ:RCM) Q4 2023 Earnings Conference Call February 27, 2024 8:00 AM ET

R1 RCM Inc. (RCM) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for R1 RCM Inc. (RCM) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, R1 RCM Inc. (RCM) Q4 Earnings: A Look at Key Metrics

R1 RCM Inc. (RCM) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.09 per share a year ago.

R1 RCM Inc. (RCM) Reports Break-Even Earnings for Q4

MURRAY, Utah, Feb. 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months and year ended December 31, 2023.

R1 RCM Reports Fourth Quarter and Full Year 2023 Results

ROWAYTON, Conn.--(BUSINESS WIRE)--Coliseum Capital Management, LLC (“Coliseum”), one of the largest shareholders of R1 RCM Inc. (NASDAQ: RCM) (“Company”), today announced that it has issued an open letter to the Company's Board of Directors. In its letter, Coliseum states that it believes the offer by New Mountain Capital, L.L.C. to acquire the Company for cash consideration of $13.75 per share significantly undervalues the Company. The letter also expresses support for the Company's Board of D.

Coliseum Capital Issues Open Letter to Board of R1 RCM on Offer by New Mountain to Acquire the Company for $13.75 Per Share

R1 RCM (RCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy R1 RCM (RCM) Ahead of Earnings?

Get a deeper insight into the potential performance of R1 RCM Inc. (RCM) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Ahead of R1 RCM Inc. (RCM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

R1 RCM Inc. (RCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

R1 RCM Inc. (RCM) Reports Next Week: Wall Street Expects Earnings Growth

MURRAY, Utah, Feb. 16, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

R1 RCM to Present at Upcoming Investor Conferences

TELUS International (Cda)

Investors with an interest in Technology Services stocks have likely encountered both Telus International (TIXT) and R1 RCM Inc. (RCM). But which of these two stocks offers value investors a better bang for their buck right now?

News for R1 RCM Inc Stock (RCM)